Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis

New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Respir J
Autors principals: Glassberg, Marilyn K., Wijsenbeek, Marlies S., Gilberg, Frank, Petzinger, Ute, Kirchgaessler, Klaus-Uwe, Albera, Carlo
Format: Artigo
Idioma:Inglês
Publicat: European Respiratory Society 2019
Matèries:
Agora
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6766683/
https://ncbi.nlm.nih.gov/pubmed/31164431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00399-2019
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars